DDInter56 DDInter899
Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischem
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Alteplase {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Alteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticlopidine
Alteplase {u} may lead to a major life threatening interaction when taken with {v} Desirudin
Alteplase {u} may lead to a major life threatening interaction when taken with {v} Lepirudin
Alteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Alteplase may lead to a major life threatening interaction when taken with Desirudin
Alteplase may lead to a major life threatening interaction when taken with Lepirudin